Aurora Medical Completes Tens of Millions RMB Series A Financing to Advance Clinical Research of Non-Invasive Cavitation Ablation

VCBeat (WeChat ID: vcbeat) has learned that Shenzhen Aosheng Medical Technology Co., Ltd. (“Aosheng Medical”), an innovative medical device company specializing in non-invasive ultrasound therapy, recently completed a Series A financing round worth tens of millions of yuan.This round of financing was co-led by Yangyun Capital and Yonghua Investment, with participation from Yijing Capital and Wanfeng Capital. Mifang Capital, the lead investor in the Pre-A round, made an additional follow-on investment.The financing proceeds will be primarily used to advance the clinical research on non-invasive ablation for benign prostatic hyperplasia (BPH) and to explore the expansion of cavitation ultrasound into other indications.

Aosheng Medical, founded in Shenzhen in 2019, is a company focused on the development of medical ultrasound diagnostic and therapeutic surgical robots.Aosheng Medical integrates R&D, manufacturing, sales, and medical services. Its current product portfolio includes the Pulsed Ultrasound Cavitation Ablation Robot (PUCA), urology-specific ultrasound, anesthesia ultrasound, and colorectal ultrasound systems. Leveraging its two core technology platforms—ultrasound and robotics—the company provides comprehensive solutions spanning tumor diagnosis, image fusion, surgical planning, interventional navigation, and non-invasive ablation therapy.

It is understood that PUCA (Pulsed Ultrasonic Cavitation Ablation) is the core technology of Aosheng Medical and represents a significant technological breakthrough.Prior to the advent of PUCA technology, the primary non-invasive surgical treatments for hyperplasia and tumors were radiation therapy and high-intensity focused ultrasound (HIFU) thermal ablation.

In addition to the risk of excessive radiation exposure and potential damage to surrounding healthy tissues, conventional radiotherapy is associated with high treatment costs. Patients often require multiple sessions, and the prohibitive cost of radiotherapy equipment—often reaching tens of millions of yuan—renders it unaffordable for most healthcare institutions.

Although traditional HIFU thermal ablation technology is relatively cost-effective, inherent theoretical limitations of the technique have posed significant challenges to its clinical adoption and widespread application.

It is difficult to accurately measure the temperature of the ablation focus inside the human body in real time, which often leads to excessive or insufficient tissue temperature, thereby affecting the actual therapeutic efficacy. Furthermore, imaging techniques cannot be used to assess the actual impact of the temperature at the margins of the treatment zone on healthy organs or to observe the condition of the ablation area. Consequently, physicians are unable to monitor the treatment progress during the procedure, resulting in poor controllability and reduced safety. Meanwhile, the ablated, coagulated, and necrotic tissue remains within the ablation zone, requiring weeks or even months to be absorbed by the body and replaced by fibrous tissue. These issues have consistently prevented traditional thermal ablation technology from becoming a sufficiently safe and effective clinical treatment tool.

The advent of PUCA technology has brought more possibilities to non-invasive ablation surgery.

PUCA technology is a non-invasive, non-radiative, and non-thermal tissue ablation technique based on ultrasound and real-time image guidance, which is fundamentally different from traditional high-intensity focused ultrasound (HIFU) thermal ablation.High-intensity focused ultrasound (HIFU) "cooks" tissue at high temperatures, causing coagulative necrosis. In contrast, PUCA employs the Boiling Histotripsy method, ultimatelyThe target tissue is immediately fragmented and liquefied into subcellular debris, which is then rapidly absorbed or metabolically excreted by the body, thereby achieving "instantaneous resection."

Since the discovery of the ultrasound microbubble phenomenon by acoustics researchers, it has been considered unpredictable and uncontrollable.However, Aosheng Medical’s PUCA protocol achieves real-time, precise control and effective utilization of the tissue-disrupting effects of ultrasound microbubbles, thereby enabling the ablation of internal tissues without the need for open surgery or intraluminal instruments.Currently, the PUCA system independently developed by Aosheng Medical has recentlyCompleted preclinical animal studies on prostate ablation, verifying its safety and efficacy in animal models.

PUCA Scientific Principle: Microbubble Cavitation Ablation

Specifically, PUCA ablation offers three major advantages.

First, millimeter-level precision. Cavitation ablation can achieve accuracy at the millimeter level, with particularly clear ablation boundaries.

Second, cavitation ablation. Leveraging the cavitation ablation principle of PUCA, target tissue is liquefied and absorbed, resulting in rapid and thorough prostate ablation.

Third, real-time control and monitoring. The ablation process can be monitored in real time via ultrasound imaging, ensuring a high degree of consistency between the ablation zone and the preoperative plan, thereby achieving “what you see is what you get” under non-invasive conditions on the body surface.

This technology enables non-invasive, real-time ablation of soft tissue without affecting the surrounding normal healthy tissues. Currently, while applying this technology platform to the ablation of benign prostatic hyperplasia (BPH), the company is also actively exploring its application in other areas, such as the ablation of other soft tissue hyperplasias and malignant tumors.

Dr. Gao Xiaobin, Chief Scientist at Aosheng Medical, stated“Ultrasound is a highly unique tool that serves both as an imaging modality to visualize internal organs and as an energy-based modality to non-invasively destroy cancer cells within the body. Furthermore, ultrasound is free from radiation and radioactivity, representing a safe and eco-friendly energy source. By integrating ultrasound technology with robotic systems and artificial intelligence as auxiliary tools, we have developed a new-generation therapeutic platform capable of precise localization and non-invasive ablation, thereby truly achieving non-invasive, precise, and green therapy.”

In addition to its core PUCA technology, Aosheng Medical has also developed the UGU series of specialized urological ultrasound systems.Targeted Fusion Biopsy of Prostate Tumors via Automatic MRI-Ultrasound Image Fusion and High-Definition Real-Time Ultrasound Guidance.The product has recently obtained an NMPA registration certificate and has been launched for commercial sale.Clinical experts who have trialed the product stated,Aosheng’s prostate image fusion navigation biopsy system delivers a user experience that surpasses imported products, and we look forward to its rapid realization of domestic substitution and upgrading for ultrasound systems dedicated to urology in China.

The company’s core team comprises senior healthcare executives, multiple PhDs in biomedical engineering, and experts and scholars from the National University of Singapore (NUS) and Nanyang Technological University (NTU) specializing in ultrasound, medical image processing, and medical robotics. The product development team consists of key technical personnel with prior experience at renowned medical enterprises, as well as software and hardware engineers with interdisciplinary backgrounds in artificial intelligence, biomedicine, medical imaging, mechatronics, and industrial design.

Moreover, Aosheng Medical has established a research and development center in Singapore and has engaged in nearly a decade of scientific research collaboration with the National University of Singapore (NUS), Nanyang Technological University (NTU), and the Agency for Science, Technology and Research (A*STAR).

Li Huan, CEO of Aosheng Medical, stated:“Minimizing surgical trauma, enhancing clinician efficiency, and reducing patient treatment costs are the mission of Aosheng Medical. Boiling Histotripsy, a non-invasive method for soft tissue ablation, achieves real-time surgical resection effects in the body while offering patients less trauma, faster recovery, and lower treatment costs. For physicians, it provides high safety and more controllable efficacy. We believe it will significantly impact future surgical practices. We thank our investors for their trust and support. In the future, the company will further expand the indications for its products to help physicians minimize patient injury. Additionally, the company’s urology-specific ultrasound product has recently received regulatory approval, enabling physicians to perform fusion image-guided targeted puncture procedures.”

Wang Sheng, Partner at Yangyun Capital, stated:Non-invasive, precision therapy represents the future of healthcare. Ultrasound cavitation ablation technology has already demonstrated strong clinical outcomes in certain applications abroad. Currently, only the Aosheng team in China has mastered this technology. We are highly optimistic about Aosheng’s ultrasound cavitation ablation technology, believing it is better suited to China’s specific healthcare landscape and holds the potential to revolutionize next-generation energy-based therapies. This innovation embodies the concept of non-invasive treatment for both benign and malignant soft tissues, serving as an invisible “cavitation scalpel” in physicians’ hands. With deep industry expertise and substantial technological accumulation, the Aosheng team is fully confident in its ability to fill the domestic gap in this field. Yangyun Capital is honored to participate in this round of financing, and we look forward to working alongside these exceptional entrepreneurs to make this “cavitation scalpel” widely accessible to the public at the earliest opportunity.

Yonghua Investment stated:We closely monitor the application of focused ultrasound technology in the medical field. This technology has already achieved some exciting results abroad. Aosheng’s technology demonstrates significant potential in the non-invasive treatment of tumors. We believe that Aosheng’s products can provide doctors and patients with a revolutionary option across multiple dimensions, including disease treatment, reduced tissue damage, and lower costs. Participating in this round of financing for Aosheng is a key component of Yonghua Investment’s strategy to actively engage in the development and upgrading of China’s medical device industry. Yonghua Investment will continue to support the growth of the medical device sector in China.

Su Zhonghe, Managing Director of Mifang Capital, stated:Driven by clinical needs and pain points, Aosheng Medical’s non-invasive, real-time controllable cavitation ablation technology is a future-oriented platform-based therapeutic solution. As a powerful tool, it empowers surgeons to achieve greater possibilities while offering patients a more cost-effective and patient-friendly option. Mifang, as an investor in the previous round, has witnessed the company’s rapid development, including the swift regulatory approval and market launch of its urological focused ultrasound product, as well as the continuous development and upcoming commercialization of additional new products. Mifang remains highly confident in the company’s future growth.

Sunmed Capital is a venture capital firm dedicated to investing in early-stage innovative medical device companies. Its management team comprises seasoned professionals with deep expertise in the domestic and international medical device industries. To date, Sunmed Capital has invested in numerous high-quality enterprises. Always considering itself an integral part of its portfolio companies, Sunmed Capital works closely with founders to provide substantial support and foster mutual growth, aiming to deliver superior products to patients and healthcare providers in China at the earliest opportunity.

Yonghua Investment is a fund management company under the Yongjin Group, specializing in private equity investment. It boasts strong competitive advantages across various stages, including investment services, industry research, sponsorship for initial public offerings (IPOs), and post-listing capital operations. Adhering to the philosophy of value investing, Yonghua Investment invests in high-quality enterprises in China with significant investment value and growth potential, thereby supporting the development of the real economy. The firm has established investment portfolios in sectors such as high-end equipment and advanced manufacturing, new energy and new materials, IT and communications technology, and pharmaceuticals and healthcare. As a professional investment institution, Yonghua Investment features a complete investment industry chain, outstanding investment performance, and extensive international resources.

Mifang Capital focuses on investments in the pharmaceutical, healthcare, and life sciences sectors, with offices in Shanghai, Beijing, and Shenzhen. The management team boasts a broad international perspective, deep industry background, extensive industry resources, and professional investment experience. The fund emphasizes “early-stage value discovery and sector opportunity identification,” focusing on investment opportunities in biopharmaceuticals, medical devices and diagnostics, and digital health. To date, it has completed investments in approximately sixty pharmaceutical companies, including Hanyu Medical, TianGuangShi, InnoMicro, Zanrong Pharma, LinkMed, PhenoGen Biologics, XinQing Medical, Libang Pharma, Anrui Biotech, Hedoo Biotech, CytoSolve Pharma, Ansong Technology, and Weiyan Medicine.

Combining “decentralized investment” with “systematic operations,” and guided by the vision of “mapping the horizon of life sciences” and the philosophy of “leveraging capital responsibly to reward trust,” Mifang Capital is committed to becoming an open, platform-based, highly competitive, and widely respected professional investment institution.

Yijing Capital, established in 2015 and headquartered in Shanghai, is a professional investment firm focused on global healthcare, cutting-edge technology, and new consumer sectors, while also managing fund-of-funds investments in these areas.

Adhering to the philosophy of “empowering corporate innovation and growth, facilitating industrial optimization and upgrading, and driving social development and progress,” the firm has grown its assets under management to RMB 7 billion, with seven portfolio companies recognized as industry-certified unicorns. Many enterprises invested in by Yijing Capital have evolved into influential leaders within their respective niche sectors. In the healthcare sector, these include Hanyu Medical, Danyi Group, Opimall, and MedSci; in frontier technology, Biren Technology, Leapmotor, Lightelligence, Qianxun Spatial Intelligence, Silan Microelectronics, and Xin Yuan Semiconductor; and in new consumption, Tasogare Coffee, Zhi Ke Tong, and Kaijie E-commerce.